Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Immatics N.V.NASDAQ: IMTX

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of €2.82M fell 10.2% year over year, behind the -2.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 10.2% from the prior quarter. Over 3 fiscal years it compounded at +19.6% a year.

Context

  • Depreciation & amortization amounted to 24.7% of revenue in FY2025, up 16.8 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -10.2% toward the trailing-twelve-month pace of -2.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€2.82M-10.2% QoQ
Last fiscal yearDec 2025
€11.91M-2.6% YoY
LTMMar 2026
€12.05M-2.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.2%——
1 year-2.6%——
3-year CAGR+19.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

EUR · from the cash flow

Latest · FY2025
11.91M EUR
Year-over-year change
-2.6%
4-year CAGR
+22.7%

Depreciation & Amortization vs competitors

How IMTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2.4% is the 3rd highest of 11, against a peer median of -12.5%.
  • Depreciation & amortization amounts to 32.3% of revenue for IMTX, versus a peer median of 9.2%.
IMTX Competitors
Depreciation & Amortization for IMTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€676.85M EUR+122.9%+43.9%25.6%
LEGNLegend Biotech CorporationLTM Sep 2026$50.27M USD+111.9%+16.3%3.7%
CLLSCellectis S.A.LTM Mar 2026$19.68M USD-2.6%+3.0%28.9%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$12.13M USD-8.0%-4.7%—
IMTXImmatics N.V.LTM Mar 2026€12.05M EUR-2.4%+19.6%32.3%
LYELLyell Immunopharma, Inc.LTM Mar 2026$10.43M USD-42.2%-11.2%33645.2%
IMCRImmunocore Holdings plcLTM Mar 2026$3.36M USD-17.0%-23.1%0.9%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$2.88M USD-18.4%-17.7%31.5%
DTILPrecision BioSciences, Inc.LTM Mar 2026$2.69M USD-30.3%-32.6%6.0%
JANXJanux Therapeutics, Inc.LTM Mar 2026$1.98M USD-3.3%+34.1%9.2%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$175K USD-96.8%-25.1%0.8%
Peer median (excluding IMTX) —-12.5%-8.0%9.2%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(93.34M)37.51M(94.65M)15.22M(188.69M)
Depreciation & Amortization5.26M6.97M7.23M12.23M11.91M
Deferred Income Tax11.15M4.52M06.13M0
Stock-Based Compensation26.4M22.57M20.71M17.64M0
Change in Working Capital(31.7M)37.26M81.63M(163.88M)(42.23M)
Accounts Receivables569K(429K)(2.98M)(1.76M)(232.45K)
Inventory00(84.24M)00
Accounts Payables(31.78M)45.56M84.24M0(36.13M)
Other Working Capital(483K)(7.87M)84.61M(162.11M)(5.87M)
Other Non-Cash Items433K(8.7M)3.31M(45.37M)49.36M
Operating Cash Flow(81.78M)100.13M18.23M(158.03M)(169.66M)
Capital Expenditures(5.66M)(6.22M)(30.96M)(16.48M)(6.3M)
Acquisitions (Net)551K(199.91M)000
Purchases of Investments(11.3M)(216.32M)(415.33M)(450.35M)(324.92M)
Sales of Investments24.45M12.7M414.74M314.44M528.16M
Other Investing Activities(551K)199.96M(8K)(206K)0
Investing Cash Flow7.49M(209.79M)(31.39M)(152.39M)196.7M
Debt Repayment(2.71M)(2.84M)(3.85M)(2.01M)0
Common Stock Issued94K134.48M90.4M343.01M96.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(7.93M)(2.04M)(21.31M)(2.84M)
Financing Cash Flow(2.61M)123.71M84.52M319.68M93.51M
Effect of Forex Changes2.37M1.48M(1.4M)9.01M16.56M
Net Change in Cash(74.54M)15.53M69.95M18.28M137.12M
Free Cash Flow(87.44M)93.92M(12.73M)(174.51M)(175.95M)

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.